The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 32551010 |
4 |
Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface. |
Dana-Farber Cancer Institute |
| 31895575 |
37 |
Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of |
East China Normal University and Shanghai Fengxian District Central Hospital Joint Center For Translational Medicine |
| 32275432 |
49 |
Achieving |
TBA |
| 31361481 |
23 |
Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles. |
Astrazeneca |
| 29555420 |
2 |
A genetically selected cyclic peptide inhibitor of BCL6 homodimerization. |
University of Southampton |
| 29969259 |
21 |
Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design. |
University of Maryland |
| 28471657 |
18 |
Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach. |
Takeda Pharmaceutical |
| 28760529 |
7 |
Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design. |
Takeda Pharmaceutical |
| 29328660 |
8 |
X-ray Structures of Target-Ligand Complexes Containing Compounds with Assay Interference Potential. |
Rheinische Friedrich-Wilhelms-Universit£T |
| 28485934 |
48 |
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors. |
Astrazeneca |
Search and Browse
